Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05090371 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05090371 · ClinicalTrials.gov record · last posted 2026-05-29

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Study acronym: SOSTOS
StatusActive, Not Recruiting
PhasePhase 4
Started2022-03-02
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.

Protocol amendment history 2 changes detected by DataLookout

2026-03-31
Primary completion pushed: 2026-12-31 → 2027-04-13
2026-03-31
Completion pushed: 2027-03-01 → 2027-04-13
Trial Details
NCT Number NCT05090371
Lead Sponsor Novartis Pharmaceuticals
Conditions Relapsing-Remitting Multiple Sclerosis
Enrollment 136 participants
Start Date 2022-03-02
Primary Completion 2027-04-13 (estimated)
Study Completion 2027-04-13 (estimated)
Updated on ClinicalTrials.gov 2026-05-29